

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 8-K

ELITE PHARMACEUTICALS INC /DE/
Form 8-K
July 29, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

July 28, 2004

(Date of Report)

ELITE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

| | | |
|---|-----------------------------|--------------------------------------|
| Delaware | 333-45241 | 22-3542636 |
| ----- | ----- | ----- |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

165 Ludlow Avenue, Northvale, New Jersey 07647

(Address of principal executive offices)

(201) 750-2646

(Registrant's telephone number, including area code)

Item 5. OTHER EVENTS AND REGULATION FD DISCLOSURE

The Registrant issued on July 28, 2004, a press release announcing it has amended its Certificate of Incorporation to increase its authorized shares of capital stock from 25,000,000 shares of Common Stock, par value \$0.01 per share, to 65,000,000 shares of Common Stock, par value \$0.01 per share and 5,000,000 shares of Preferred Stock, par value \$0.01 per share. The amendment to the Certificate of Incorporation was approved by the Registrant's stockholders at its adjourned Annual Meeting of the Stockholders.

A copy of Registrant's press release is attached as Exhibit 99.1 and a certified copy of the Certificate of Amendment of the Certificate of Incorporation of the Registrant is filed as exhibit 3.1

Item 7. FINANCIAL STATEMENTS AND EXHIBITS

- a) Not applicable.
- b) Not applicable.

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 8-K

- c) Exhibits
 - 3.1 Certified copy of the Certificate of Amendment of the Certificate of Incorporation filed with the Secretary of State of Delaware on July 26, 2004.
 - 99.1. Press Release, dated May 14, 2004

-2-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 28, 2004

ELITE PHARMACEUTICALS, INC.

By: /s/ Bernard Berk

Name: Bernard Berk
Title: Chief Executive Officer